Prevalence of cervical cancer in the Far Eastern Federal District and ways to improve early detection of the disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To investigate the prevalence, mortality, and detection rate of cervical cancer in the Far Eastern Federal District for the development and implementation of a cervical cancer screening program aimed to reduce mortality in the female population. Materials and methods. The study used statistical and analytical methods, including a retrospective analysis of official statistical indicators for cervical cancer in eight federal districts of the Russian Federation and 11 subjects of the Far Eastern Federal District, with a subsequent mathematical interpretation of the data. Mean values were calculated according to the generally accepted statistical methods. Results. In the Far Eastern Federal District, incidence rates of cervical cancer for the years 2014-2017 ranged from 17.33 to 21.36per 100,000 of female population, which were greater than that in the Russian Federation (from 14.47to 15.76, respectively). In 2018, the Far East Federal District had the highest prevalence of cervical cancer in the Russian Federation (152.3 vs.123.7 per 100,000 of female population). Regional problems include low cervical screening coverage for the female population aged 21-69 at 50.53% (CI 10.0-78.7%) (target> 70%) and active detection of cervical cancer at 48.58% ( CI 33.51-66.7%) (target indicator for stage I - II cervical cancer identifiable by visual inspection> 70%). Conclusion. The Far Eastern Federal District has the highest prevalence of cervical cancer, which requires the active implementation of an organized cervical screening program based on human papillomavirus and cytology co-testing and accessible to people living in remote rural areas of the region.

Full Text

Restricted Access

About the authors

Tatiana E. Belokrinitskaya

Chita State Medical Academy of the Ministry of Health of Russia

Email: tanbell24@mail.ru

Oleg S. Filippov

A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia

Email: fllippovolsem@yandex.ru

Nataly I. Frolova

Chita State Medical Academy of the Ministry of Health of Russia

Email: taasyaa@mail.ru

References

  1. Bruni L., Albero G., Serrano B., Mena M., Gomez D., Munoz J. et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report. 2019. 315 p. URL: https://www.hpvcentre.net/statistics/reports/XWX.pdf
  2. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2018 году. М., 2019. 236 с.
  3. Schiffman M., Doorbar J., Wentzensen N., de Sanjose S., Fakhry C., Monk B.J. et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016; 2: 16086. doi: 10.1038/nrdp.2016.86.
  4. Сухих Г.Т., Прилепская В.Н., ред. Профилактика рака шейки матки: руководство для врачей. Изд. 3-е. М.: МЕДпресс-информ, 2012. 190c.
  5. WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. World Health Organization; 2013. 13 р.
  6. Каприн А.Д., Новикова Е.Г., Трушина О.И., Грецова О.П. Скрининг рака шейки матки - нерешенные проблемы. Исследования и практика в медицине. 2015; 2(1): 36-41. doi: 10.17709/2409-2231-2015-2-1-36-41
  7. Фролова Н.И., Белокриницкая Т.Е., Баркан Т.М., Голыгин Е.В., Лига В.Ф., Плетнева В.А. и др. Медико-социальная характеристика женщин молодого фертильного возраста, перенесших гистерэктомию. Acta Biomedica Scientifica. 2018; 3(4): 15-20. doi: 10.29413/ ABS.2018-3.4.2
  8. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М., 2018. 250 с.
  9. Адамян Л.В., Артымук Н.В., Белокриницкая Т.Е., Корженкова Г.П., Протасова А.Э., Рожкова Н.И. и др. Доброкачественные и предраковые заболевания шейки матки с позиции профилактики рака. Клинические рекомендации (протоколы лечения). Проблемы репродукции. 2018; 24(S6): 775-802.
  10. Белокриницкая Т.Е., Фролова Н.И., Туранова О.В., Шемякина К.Н., Плетнева В.А. и др. Результативность и приемлемость обследования на вирус папилломы человека при самостоятельном и врачебном заборе вагинального отделяемого. Акушерство и гинекология. 2017; 2: 97-105. http:// dx.doi.org/10.18565
  11. Chou H.H., Huang H.J., Cheng H.H., Chang C.J., Yang L.Y., Huang C.C. et al. Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. J Formos Med Assoc. 2016; 115(12): 1089-96. doi: 10.1016 /j.jfma.2015.10.014
  12. Verdoodt F., Jentschke M., Hillemanns P., Racey C.S., Snijders P.J., Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015; 51(16): 2375-85. doi: 10.1016/j. ejca.2015.07.006
  13. von Karsa L., Arbyn M., De Vuyst H., Dillner J., Dillner L., Franceschi S. et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015; 1: 22-31. doi: 10.1016/j.pvr.2015.06.006

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies